AIVIVA BIOPHARMA INC has a total of 38 patent applications. It decreased the IP activity by 16.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and measurement are KLARIA PHARMA HOLDING AB, BIO BEDST APS and TECHNI PHARMA.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | Australia | 6 | |
#3 | EPO (European Patent Office) | 6 | |
#4 | Canada | 5 | |
#5 | Republic of Korea | 5 | |
#6 | WIPO (World Intellectual Property Organization) | 4 | |
#7 | China | 3 | |
#8 | Taiwan | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Tang-Liu Diane | 25 |
#2 | Devries Gerald Woodrow | 23 |
#3 | Liu Tiffany Constance | 14 |
#4 | Ding Shulin | 9 |
#5 | Muhuri Goutam | 7 |
#6 | Tang-Liu Diane Dan-Shya | 4 |
#7 | Liu Tiffany | 4 |
#8 | Dan-Shya Tang-Liu Diane | 3 |
#9 | Tang Liu Diane | 3 |
#10 | Devries Gerald | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020112655A1 | Pharmaceutical biodissolvable gels for drug delivery | |
AU2019321429A1 | Multi-kinase inhibitors of VEGF and TGF beta and uses thereof | |
AU2018317352A1 | Multikinase inhibitors and uses in reproductive and digestive tract fibrosis | |
US2020345637A1 | Suspension compositions of multi-target inhibitors | |
CN111655339A | Multikinase inhibitors and their use in prostate hyperplasia and urinary tract disorders | |
US2019275034A1 | Multikinase inhibitors and uses in ocular fibrosis | |
US2019388407A1 | Multikinase inhibitors of vegf and tfg beta and uses thereof | |
EP3359258A1 | Compositions and methods of treating skin fibrotic disorders |